Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 2014;37:2149–2158

Detalles Bibliográficos
Autores principales: Nauck, Michael, Weinstock, Ruth S., Umpierrez, Guillermo E., Guerci, Bruno, Skrivanek, Zachary, Milicevic, Zvonko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2015
Materias:
Erratum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321253/
https://www.ncbi.nlm.nih.gov/pubmed/25715416
http://dx.doi.org/10.2337/dc15-er03
_version_ 1782509658997522432
author Nauck, Michael
Weinstock, Ruth S.
Umpierrez, Guillermo E.
Guerci, Bruno
Skrivanek, Zachary
Milicevic, Zvonko
author_facet Nauck, Michael
Weinstock, Ruth S.
Umpierrez, Guillermo E.
Guerci, Bruno
Skrivanek, Zachary
Milicevic, Zvonko
author_sort Nauck, Michael
collection PubMed
description
format Online
Article
Text
id pubmed-5321253
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-53212532017-03-07 Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 2014;37:2149–2158 Nauck, Michael Weinstock, Ruth S. Umpierrez, Guillermo E. Guerci, Bruno Skrivanek, Zachary Milicevic, Zvonko Diabetes Care Erratum American Diabetes Association 2015-03 2015-02-12 /pmc/articles/PMC5321253/ /pubmed/25715416 http://dx.doi.org/10.2337/dc15-er03 Text en © 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
spellingShingle Erratum
Nauck, Michael
Weinstock, Ruth S.
Umpierrez, Guillermo E.
Guerci, Bruno
Skrivanek, Zachary
Milicevic, Zvonko
Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 2014;37:2149–2158
title Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 2014;37:2149–2158
title_full Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 2014;37:2149–2158
title_fullStr Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 2014;37:2149–2158
title_full_unstemmed Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 2014;37:2149–2158
title_short Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 2014;37:2149–2158
title_sort efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (award-5). diabetes care 2014;37:2149–2158
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321253/
https://www.ncbi.nlm.nih.gov/pubmed/25715416
http://dx.doi.org/10.2337/dc15-er03
work_keys_str_mv AT nauckmichael efficacyandsafetyofdulaglutideversussitagliptinafter52weeksintype2diabetesinarandomizedcontrolledtrialaward5diabetescare20143721492158
AT weinstockruths efficacyandsafetyofdulaglutideversussitagliptinafter52weeksintype2diabetesinarandomizedcontrolledtrialaward5diabetescare20143721492158
AT umpierrezguillermoe efficacyandsafetyofdulaglutideversussitagliptinafter52weeksintype2diabetesinarandomizedcontrolledtrialaward5diabetescare20143721492158
AT guercibruno efficacyandsafetyofdulaglutideversussitagliptinafter52weeksintype2diabetesinarandomizedcontrolledtrialaward5diabetescare20143721492158
AT skrivanekzachary efficacyandsafetyofdulaglutideversussitagliptinafter52weeksintype2diabetesinarandomizedcontrolledtrialaward5diabetescare20143721492158
AT miliceviczvonko efficacyandsafetyofdulaglutideversussitagliptinafter52weeksintype2diabetesinarandomizedcontrolledtrialaward5diabetescare20143721492158

Ejemplares similares